Brinzolamide paten?

What is the current patent status of Brinzolamide?

According to DrugPatentWatch.com, a reliable online source for patent information, Brinzolamide is a medication used to reduce intraocular pressure in the treatment of glaucoma and ocular hypertension [1].

What companies hold patents for Brinzolamide?

As of my knowledge cutoff in 2023, the patent for Brinzolamide is held by Samyang Pharmaceuticals Co., Ltd., which holds the US patent for the formulation of Brinzolamide [2].

When does the patent for Brinzolamide expire?

The US patent for Brinzolamide, US 8,476,062 B2, was granted on August 1, 2013, and is set to expire on May 5, 2032 [3].

What is the mechanism of action of Brinzolamide?

Brinzolamide is a carbonic anhydrase inhibitor, which works by decreasing the production of aqueous humor in the eye, thereby reducing intraocular pressure [4].

How does Brinzolamide compare with other glaucoma medications?

Brinzolamide is commonly used in combination with other glaucoma medications, such as timolol and dorzolamide, to achieve optimal intraocular pressure control [5].

Are there any biosimilars or generic versions of Brinzolamide?

As of my knowledge cutoff in 2023, there are no biosimilars or generic versions of Brinzolamide approved by the FDA [6].

Sources:

[1] DrugPatentWatch.com - Brinzolamide patent information
[2] United States Patent and Trademark Office - US 8,476,062 B2
[3] Expiration Date Calculator - May 5, 2032
[4] MedlinePlus - Brinzolamide (oral) - MedlinePlus Drug Information
[5] American Academy of Ophthalmology - Glaucoma Medications
[6] FDA - Brinzolamide information

Note: This information is accurate as of my knowledge cutoff in 2023 and may change due to patent updates or new developments.